Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) announced that the underwriter of its initial public offering (the 'Offering') have exercised in full their option to purchase an additional 225,000 ordinary shares at a public offering price of $4.00 per ordinary share to cover over-allotments. The gross proceeds of the Company's initial public offering, including the exercise of the over-allotment, totaled $6.9 million, before deducting underwriting discounts and other related expenses. Proceeds from the Offering will be used for acquiring vaccine production companies and conducting R&D projects.